Glioblastoma (GBM) is the deadliest and most common form of glioma, with a median survival less than two years after diagnosis. Although current therapies reduce progression, outcomes for these patients are dismal. We propose that glioblastoma cells, like most cancer cells, adapt their surrounding microenvironment to support their growth, invasion and metabolic needs. This is accomplished largely through the secretion of factors that activate autocrine and paracrine signaling cascades, and thus create vicious positive feedback loops, disrupt normal tissue homeostasis and promote malignancy. Therapeutic targeting of not only the tumor cells, but also the of tumor microenvironment (TME) is a proposed strategy to improve patient outcome. Treatment failure in glioblastoma is attributed in part to the persistence of glioma stem cells, highly resistant to therapies currently employed, and also to inefficient drug delivery into the tumor. Our data demonstrates that the CXCL12 chemokine operates through an autocrine-positive feedback mechanism, to promote survival and cell-cycle progression of GBM stem cells. Targeting this signaling axis using pharmacologic agents prolongs survival of animals with GBM, yet efficacy of treatment is limited by inadequate drug distribution within the tumor. Non-cancerous neural stem cells naturally migrate and distribute within brain tumors, traversing the blood brain barrier and surpassing limitations brought about by the dysfunctional vasculature within GBM. This study addresses the need for better GBM treatments by targeting the TME, using engineered stem cells designed to scavenge cancer promoting cytokine and inhibit tumor growth. To accomplish this, first we will generate stem cells able to detect levels of CXCL12 and Tgf? and in response to lower their levels and effects. These parameters will be tested and optimized in a series of in vitro experiments. Secondly, efficiency of these cells to migrate into the tumor, modify the TME and inhibit tumor growth will be tested in an optimized model of GBM, which recapitulates the salient features of human disease. Data generated from this study will be important in establishing therapeutically functional regimens using engineered cytokine converter cells and will lay the foundations for further optimizations and improvement of this safe and novel therapeutic approach. Results from these experiments will further our knowledge in the field of theranostic agents for treatment and live monitoring of disease progression and open up numerous avenues for further exploration. 1/1

Public Health Relevance

/Lay Summary Glioblastoma (GBM) is the deadliest and most common form of malignant brain tumor, with median survival after diagnosis of less than two years. Although current therapies reduce progression, outcomes for these patients are dismal. This study aims to improve current therapies for GBM by implementing a novel therapeutic approach with engineered stem cells, designed to remove cancer promoting factors and render the tumor microenvironment refractory for tumor growth.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Clinical Neuroimmunology and Brain Tumors Study Section (CNBT)
Program Officer
Fountain, Jane W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Schools of Medicine
Ann Arbor
United States
Zip Code